Northwestern Mutual Wealth Management Co. Takes $537,000 Position in Illumina, Inc. $ILMN

Northwestern Mutual Wealth Management Co. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,056 shares of the life sciences company’s stock, valued at approximately $537,000.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Illumina in the 2nd quarter worth about $3,374,423,000. WCM Investment Management LLC grew its stake in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the period. Bank of New York Mellon Corp acquired a new stake in Illumina during the second quarter worth approximately $293,846,000. Invesco Ltd. increased its holdings in Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after purchasing an additional 1,352,731 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after buying an additional 1,028,099 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on ILMN shares. Canaccord Genuity Group raised their price objective on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. TD Cowen lifted their price target on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Barclays upped their price objective on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Finally, Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $188.40.

Insider Buying and Selling

In other Illumina news, Director Keith A. Meister sold 299,336 shares of Illumina stock in a transaction on Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the transaction, the director directly owned 1,409,851 shares of the company’s stock, valued at $307,291,123.96. The trade was a 17.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Scott M. Davies sold 615 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the sale, the insider owned 20,338 shares of the company’s stock, valued at approximately $4,067,600. This represents a 2.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,874,458 shares of company stock worth $367,996,424. 2.90% of the stock is owned by corporate insiders.

Illumina Stock Down 0.1%

Shares of NASDAQ ILMN opened at $224.84 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a 50-day moving average price of $191.66 and a 200-day moving average price of $154.42. The stock has a market capitalization of $33.95 billion, a P/E ratio of 41.95, a P/E/G ratio of 3.17 and a beta of 1.45. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $227.70.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.